Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Eton Pharmaceuticals(US:ETON) Globenewswire·2026-03-19 20:05Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 millionLaunched DESMODA™, the first and only FDA-approved desmopressin oral solutionLicensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earningsCompany expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30 ...